HOTH - Hoth Therapeutics Announces Its New Product Ht-Alz Therapeutic Gives Cognitive Improvements In Alzheimer's Disease Model In Mouse

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical, announced today proof-of-concept data recorded using cognitive and behavioral assessments in an Alzheimer’s disease mouse model (aged APP/PS1+/- mice), indicating that HT-ALZ has cognitive therapeutic potential after chronic oral dosing. The study was carried out as part of a Sponsored Research Agreement between the firm and Washington University in St. Louis. HT-ALZ is a medication in development for the treatment of dementia associated with Alzheimer’s disease through the 505(b)(2) regulatory procedure (AD).

Carla Yuede, Ph.D., Associate Professor of Psychiatry, and John Cirrito, Ph.D., Associate Professor of Neurology, of ...